首页 > 最新文献

BJR open最新文献

英文 中文
"Advances in cancer imaging and technology"-special collection -introductory Editorial. “癌症成像和技术的进展”-特辑-导论社论
Pub Date : 2022-12-07 eCollection Date: 2022-01-01 DOI: 10.1259/bjro.20229003
Zuhir Bodalal, Sharyn Katz, Haibin Shi, Regina Beets-Tan
{"title":"\"Advances in cancer imaging and technology\"-special collection -introductory Editorial.","authors":"Zuhir Bodalal, Sharyn Katz, Haibin Shi, Regina Beets-Tan","doi":"10.1259/bjro.20229003","DOIUrl":"10.1259/bjro.20229003","url":null,"abstract":"","PeriodicalId":72419,"journal":{"name":"BJR open","volume":" ","pages":"20229003"},"PeriodicalIF":0.0,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10959000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49075206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stereotactic prostate radiotherapy with or without androgen deprivation therapy, study protocol for a phase III, multi-institutional randomized-controlled trial. 立体定向前列腺放疗伴或不伴雄激素剥夺治疗,III期多机构随机对照试验研究方案
Pub Date : 2022-11-29 eCollection Date: 2022-01-01 DOI: 10.1259/bjro.20220032
Marco Lorenzo Bonù, Alessandro Magli, Davide Tomasini, Francesco Frassine, Domenico Albano, Stefano Arcangeli, Alessio Bruni, Stefano Ciccarelli, Martina De Angeli, Giulio Francolini, Ciro Franzese, Paolo Ghirardelli, Luigi Grazioli, Andrea Guerini, Andrea Lancia, Giulia Marvaso, Matteo Sepulcri, Luca Eolo Trodella, Vittorio Morelli, Andrea Georgopulos, Anastasiya Oleksandrivna Domina, Lorenzo Granello, Eneida Mataj, Fernando Barbera, Luca Triggiani

Objective: The therapeutic landscape for localized prostate cancer (PC) is evolving. Stereotactic radiotherapy (SRT) has been reported to be at least not inferior to standard radiotherapy, but the effect of androgen deprivation therapy (ADT) in this setting is still unknown and its use is left to clinical judgment. There is therefore the need to clarify the role of ADT in association with SRT, which is the aim of the present study.

Methods: We present a study protocol for a randomized, multi-institutional, Phase III clinical trial, designed to study SRT in unfavorable intermediate and a subclass of high-risk localized PC. Patients (pts) will be randomized 1:1 to SRT + ADT or SRT alone. SRT will consists in 36.25 Gy in 5 fractions, ADT will be a single administration of Triptorelin 22.5 mg concurrent to SRT. Primary end point will be biochemical disease-free survival. Secondary end points will be disease-free survival, freedom from local recurrence, freedom from regional recurrence, freedom from distant metastasis and overall survival (OS); quality of life QoL and patient reported outcomes will be an exploratory end point and will be scored with EPIC-26, EORTC PR 25, IPSS, IIEF questionnaires in SRT + ADT and SRT alone arms. Moreover, clinician reported acute and late toxicity, assessed with CTCAE v. 5.0 scales will be safety end points.

Results: Sample size is estimated of 310 pts. For acute toxicity and quality of life results are awaited after 6 months since last patient in, whereas, for efficacy end points and late toxicity mature results will be available 3-5 years after last patient in.

Conclusion: Evidence is insufficient to guide decision making concerning ADT administration in the new scenario of prostate ultra-hypofractionation. Hence, the need to investigate the ADT role in SRT specific setting.

Advances in knowledge: The stereotactic prostate radiotherapy with or without ADT trial (SPA Trial) has been designed to establish a new standard of care for SRT in localized unfavorable intermediate and a subclass of localized high risk PC.

局限性前列腺癌(PC)的治疗前景正在发展。立体定向放疗(SRT)至少不逊于标准放疗,但雄激素剥夺疗法(ADT)在这种情况下的效果尚不清楚,其使用尚待临床判断。因此,有必要澄清ADT与SRT相关的作用,这是本研究的目的。我们提出了一项随机、多机构、三期临床试验的研究方案,旨在研究SRT在不利的中间和高风险局部PC的亚类中的应用。患者(pts)将按1:1随机分配到SRT + ADT或单独SRT。SRT将分为五个部分,共36.25 Gy, ADT将是在SRT的同时单次给予Triptorelin 22.5 mg。主要终点为生化无病生存期(bDFS)。次要终点将是无病生存期(DFS)、无局部复发(FFLR)、无区域复发(FFRR)、无远处转移(FFDM)和总生存期(OS);生活质量(QoL)和患者报告结果(PRO)将是一个探索性终点,并将在SRT + ADT和SRT单独组中使用EPIC-26、EORTC PR 25、IPSS和IIEF问卷进行评分。此外,临床医生报告的急性和晚期毒性,用CTCAE v5.0量表评估将是安全终点。样本量估计为310分。对于急性毒性和生活质量的结果要在最后一位患者入院后6个月后才能得到,而对于疗效终点和晚期毒性的成熟结果要在最后一位患者入院后3至5年才能得到。证据不足,指导决策有关ADT给药的新情况下,前列腺超低分割。因此,有必要研究ADT在SRT特定环境中的作用。立体定向前列腺放疗加或不加雄激素剥夺治疗试验(SPA试验)的目的是为局部不良中度和局部高危前列腺癌的SRT治疗建立一个新的标准。
{"title":"Stereotactic prostate radiotherapy with or without androgen deprivation therapy, study protocol for a phase III, multi-institutional randomized-controlled trial.","authors":"Marco Lorenzo Bonù, Alessandro Magli, Davide Tomasini, Francesco Frassine, Domenico Albano, Stefano Arcangeli, Alessio Bruni, Stefano Ciccarelli, Martina De Angeli, Giulio Francolini, Ciro Franzese, Paolo Ghirardelli, Luigi Grazioli, Andrea Guerini, Andrea Lancia, Giulia Marvaso, Matteo Sepulcri, Luca Eolo Trodella, Vittorio Morelli, Andrea Georgopulos, Anastasiya Oleksandrivna Domina, Lorenzo Granello, Eneida Mataj, Fernando Barbera, Luca Triggiani","doi":"10.1259/bjro.20220032","DOIUrl":"10.1259/bjro.20220032","url":null,"abstract":"<p><strong>Objective: </strong>The therapeutic landscape for localized prostate cancer (PC) is evolving. Stereotactic radiotherapy (SRT) has been reported to be at least not inferior to standard radiotherapy, but the effect of androgen deprivation therapy (ADT) in this setting is still unknown and its use is left to clinical judgment. There is therefore the need to clarify the role of ADT in association with SRT, which is the aim of the present study.</p><p><strong>Methods: </strong>We present a study protocol for a randomized, multi-institutional, Phase III clinical trial, designed to study SRT in unfavorable intermediate and a subclass of high-risk localized PC. Patients (pts) will be randomized 1:1 to SRT + ADT or SRT alone. SRT will consists in 36.25 Gy in 5 fractions, ADT will be a single administration of Triptorelin 22.5 mg concurrent to SRT. Primary end point will be biochemical disease-free survival. Secondary end points will be disease-free survival, freedom from local recurrence, freedom from regional recurrence, freedom from distant metastasis and overall survival (OS); quality of life QoL and patient reported outcomes will be an exploratory end point and will be scored with EPIC-26, EORTC PR 25, IPSS, IIEF questionnaires in SRT + ADT and SRT alone arms. Moreover, clinician reported acute and late toxicity, assessed with CTCAE v. 5.0 scales will be safety end points.</p><p><strong>Results: </strong>Sample size is estimated of 310 pts. For acute toxicity and quality of life results are awaited after 6 months since last patient in, whereas, for efficacy end points and late toxicity mature results will be available 3-5 years after last patient in.</p><p><strong>Conclusion: </strong>Evidence is insufficient to guide decision making concerning ADT administration in the new scenario of prostate ultra-hypofractionation. Hence, the need to investigate the ADT role in SRT specific setting.</p><p><strong>Advances in knowledge: </strong>The stereotactic prostate radiotherapy with or without ADT trial (SPA Trial) has been designed to establish a new standard of care for SRT in localized unfavorable intermediate and a subclass of localized high risk PC.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":" ","pages":"20220032"},"PeriodicalIF":0.0,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10958993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48133659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The reproducibility of manual RV/LV ratio measurement on CT pulmonary angiography. CT肺血管造影手工测量RV/LV比值的可重复性
Pub Date : 2022-11-28 eCollection Date: 2022-01-01 DOI: 10.1259/bjro.20220041
Sarah Lanham, Ahmed Maiter, Andrew J Swift, Krit Dwivedi, Samer Alabed, Oscar Evans, Michael J Sharkey, Suzanne Matthews, Christopher S Johns

Objectives: Right ventricular (RV) dysfunction carries elevated risk in acute pulmonary embolism (PE). An increased ratio between the size of the right and left ventricles (RV/LV ratio) is a biomarker of RV dysfunction. This study evaluated the reproducibility of RV/LV ratio measurement on CT pulmonary angiography (CTPA).

Methods: 20 inpatient CTPA scans performed to assess for acute PE were retrospectively identified from a tertiary UK centre. Each scan was evaluated by 14 radiologists who provided a qualitative overall opinion on the presence of RV dysfunction and measured the RV/LV ratio. Using a threshold of 1.0, the RV/LV ratio measurements were classified as positive (≥1.0) or negative (<1.0) for RV dysfunction. Interobserver agreement was quantified using the Fleiss κ and intraclass correlation coefficient (ICC).

Results: Qualitative opinion of RV dysfunction showed weak agreement (κ = 0.42, 95% CI 0.37-0.46). The mean RV/LV ratio measurement for all cases was 1.28 ± 0.68 with significant variation between reporters (p < 0.001). Although agreement for RV/LV measurement was good (ICC = 0.83, 95% CI 0.73-0.91), categorisation of RV dysfunction according to RV/LV ratio measurements showed weak agreement (κ = 0.46, 95% CI 0.41-0.50).

Conclusion: Both qualitative opinion and quantitative manual RV/LV ratio measurement show poor agreement for identifying RV dysfunction on CTPA.

Advances in knowledge: Caution should be exerted if using manual RV/LV ratio measurements to inform clinical risk stratification and management decisions.

右心室(RV)功能障碍会增加急性肺栓塞(PE)的风险。右心室和左心室大小之间的比率(RV/LV比率)增加是RV功能障碍的生物标志物。本研究评估了CT肺动脉造影(CTPA)中RV/LV比值测量的可重复性。从英国一家三级中心对20名住院患者进行CTPA扫描以评估急性PE进行了回顾性鉴定。每次扫描都由14名放射科医生进行评估,他们对RV功能障碍的存在提供了定性的总体意见,并测量了RV/LV比率。使用1.0的阈值,RV/LV比率测量被分为RV功能障碍的阳性(≥1.0)或阴性(<1.0)。使用κ(κ)和组内相关系数(ICC)量化观察者之间的一致性。RV功能障碍的定性意见显示弱一致性(κ=0.42,95% CI 0.37–0.46)。所有病例的平均RV/LV比值测量值为1.28±0.68,报告者之间存在显著差异(p<0.001)。尽管RV/LV测量值一致性良好(ICC=0.83,95% CI 0.73–0.91),根据RV/LV比率测量对RV功能障碍的分类显示出微弱的一致性(κ=0.46,95% CI 0.41–0.50)。定性意见和定量手动RV/LV比值测量显示,在CTPA上识别RV功能障碍的一致性较差。如果使用手动RV/LV比率测量来告知临床风险分层和管理决策,则应注意。
{"title":"The reproducibility of manual RV/LV ratio measurement on CT pulmonary angiography.","authors":"Sarah Lanham, Ahmed Maiter, Andrew J Swift, Krit Dwivedi, Samer Alabed, Oscar Evans, Michael J Sharkey, Suzanne Matthews, Christopher S Johns","doi":"10.1259/bjro.20220041","DOIUrl":"10.1259/bjro.20220041","url":null,"abstract":"<p><strong>Objectives: </strong>Right ventricular (RV) dysfunction carries elevated risk in acute pulmonary embolism (PE). An increased ratio between the size of the right and left ventricles (RV/LV ratio) is a biomarker of RV dysfunction. This study evaluated the reproducibility of RV/LV ratio measurement on CT pulmonary angiography (CTPA).</p><p><strong>Methods: </strong>20 inpatient CTPA scans performed to assess for acute PE were retrospectively identified from a tertiary UK centre. Each scan was evaluated by 14 radiologists who provided a qualitative overall opinion on the presence of RV dysfunction and measured the RV/LV ratio. Using a threshold of 1.0, the RV/LV ratio measurements were classified as positive (≥1.0) or negative (<1.0) for RV dysfunction. Interobserver agreement was quantified using the Fleiss κ and intraclass correlation coefficient (ICC).</p><p><strong>Results: </strong>Qualitative opinion of RV dysfunction showed weak agreement (κ = 0.42, 95% CI 0.37-0.46). The mean RV/LV ratio measurement for all cases was 1.28 ± 0.68 with significant variation between reporters (<i>p</i> < 0.001). Although agreement for RV/LV measurement was good (ICC = 0.83, 95% CI 0.73-0.91), categorisation of RV dysfunction according to RV/LV ratio measurements showed weak agreement (κ = 0.46, 95% CI 0.41-0.50).</p><p><strong>Conclusion: </strong>Both qualitative opinion and quantitative manual RV/LV ratio measurement show poor agreement for identifying RV dysfunction on CTPA.</p><p><strong>Advances in knowledge: </strong>Caution should be exerted if using manual RV/LV ratio measurements to inform clinical risk stratification and management decisions.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":"1 1","pages":"20220041"},"PeriodicalIF":0.0,"publicationDate":"2022-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42829408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of a new acrylic-lead shielding device for peripheral dose reduction during cone-beam computed tomography. 一种新型丙烯酸铅屏蔽装置在锥束计算机断层扫描中降低外周剂量的评价
Pub Date : 2022-11-28 eCollection Date: 2022-01-01 DOI: 10.1259/bjro.20220043
Hidetoshi Shimizu, Koji Sasaki, Takahiro Aoyama, Tohru Iwata, Tomoki Kitagawa, Takeshi Kodaira

Objective: To clarify the peripheral dose changes, especially in the eye lens and thyroid gland regions, using an acrylic-lead shield in cone-beam computed tomography (CBCT).

Methods: The acrylic-lead shield consists of system walls and a system mat. The radiophotoluminescence glass dosemeter was set on the eye lens and thyroid gland regions on the RANDO phantom. The system mat was laid under the RANDO phantom ranging from the top of the head to the shoulders, and then, the system walls shielded the phantom's head. Additionally, the phantom was covered anteriorly with a band that had the same shielding ability as the system mat to cover the thyroid gland region. Protocols for CBCT imaging of the thoracic or pelvic region in clinical practice were used. The measurement was performed with and without the acrylic-lead shield.

Results: The dose to the eye lens region was reduced by 45% using the system wall. Conversely, the dose to the thyroid gland was unchanged. The use of the system mat reduced the dose to the thyroid gland region by 47%, and the dose to the eye lens was reduced by 22%. The dose to the eye lens region decreased to the background level using the system walls and mat.

Conclusion: The newly proposed device using an acrylic-lead shield reduced the peripheral dose in CBCT imaging.

Advances in knowledge: Attention is focused on managing peripheral dose in image-guided radiation therapy. The peripheral dose reduction using the acrylic-lead shield is a new proposal in radiotherapy that has never been studied.

在锥形束计算机断层扫描(CBCT)中使用丙烯酸铅屏蔽,以阐明外周剂量变化,特别是在晶状体和甲状腺区域。丙烯酸铅屏蔽由系统壁和系统垫组成。辐射光致发光玻璃剂量计设置在RANDO体模的晶状体和甲状腺区域。系统垫被放置在RANDO幻影下,从头顶到肩膀,然后,系统壁屏蔽了幻影的头部。此外,体模的前部覆盖有一条带,该带与覆盖甲状腺区域的系统垫具有相同的屏蔽能力。临床实践中使用了胸部或骨盆区域的CBCT成像方案。在有和没有丙烯酸铅屏蔽的情况下进行测量。使用系统壁,对眼睛晶状体区域的剂量减少了45%。相反,甲状腺的剂量没有变化。系统垫的使用使甲状腺区域的剂量减少了47%,而晶状体的剂量则减少了22%。使用系统壁和垫子,眼睛晶状体区域的剂量降低到背景水平。新提出的使用丙烯酸铅屏蔽的设备降低了CBCT成像中的外围剂量。在图像引导的放射治疗中,注意力集中在管理外周剂量上。使用丙烯酸铅屏蔽减少外周剂量是放射治疗中一项从未被研究过的新提议。
{"title":"Evaluation of a new acrylic-lead shielding device for peripheral dose reduction during cone-beam computed tomography.","authors":"Hidetoshi Shimizu, Koji Sasaki, Takahiro Aoyama, Tohru Iwata, Tomoki Kitagawa, Takeshi Kodaira","doi":"10.1259/bjro.20220043","DOIUrl":"10.1259/bjro.20220043","url":null,"abstract":"<p><strong>Objective: </strong>To clarify the peripheral dose changes, especially in the eye lens and thyroid gland regions, using an acrylic-lead shield in cone-beam computed tomography (CBCT).</p><p><strong>Methods: </strong>The acrylic-lead shield consists of system walls and a system mat. The radiophotoluminescence glass dosemeter was set on the eye lens and thyroid gland regions on the RANDO phantom. The system mat was laid under the RANDO phantom ranging from the top of the head to the shoulders, and then, the system walls shielded the phantom's head. Additionally, the phantom was covered anteriorly with a band that had the same shielding ability as the system mat to cover the thyroid gland region. Protocols for CBCT imaging of the thoracic or pelvic region in clinical practice were used. The measurement was performed with and without the acrylic-lead shield.</p><p><strong>Results: </strong>The dose to the eye lens region was reduced by 45% using the system wall. Conversely, the dose to the thyroid gland was unchanged. The use of the system mat reduced the dose to the thyroid gland region by 47%, and the dose to the eye lens was reduced by 22%. The dose to the eye lens region decreased to the background level using the system walls and mat.</p><p><strong>Conclusion: </strong>The newly proposed device using an acrylic-lead shield reduced the peripheral dose in CBCT imaging.</p><p><strong>Advances in knowledge: </strong>Attention is focused on managing peripheral dose in image-guided radiation therapy. The peripheral dose reduction using the acrylic-lead shield is a new proposal in radiotherapy that has never been studied.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":" ","pages":"20220043"},"PeriodicalIF":0.0,"publicationDate":"2022-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10958996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48868742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiobiological evaluation considering the treatment time with stereotactic radiosurgery for brain metastases. 考虑立体定向放射外科治疗时间的脑转移瘤放射生物学评价
Pub Date : 2022-11-24 eCollection Date: 2022-01-01 DOI: 10.1259/bjro.20220013
Hisashi Nakano, Takeshi Takizawa, Daisuke Kawahara, Satoshi Tanabe, Satoru Utsunomiya, Motoki Kaidu, Katsuya Maruyama, Shigekazu Takeuchi, Kiyoshi Onda, Masahiko Koizumi, Teiji Nishio, Hiroyuki Ishikawa

Objective: We evaluated the radiobiological effect of the irradiation time with the interruption time of stereotactic radiosurgery (SRS) using CyberKnife® (CK) systemfor brain metastases.

Methods: We used the DICOM data and irradiation log file of the 10 patients with brain metastases from non-small-cell lung cancer (NSCLC) who underwent brain SRS. We defined the treatment time as the sum of the dose-delivery time and the interruption time during irradiations, and we used a microdosimetric kinetic model (MKM) to evaluate the radiobiological effects of the treatment time. The biological parameters, i.e. α0, β0, and the DNA repair constant rate (a + c), were acquired from NCI-H460 cell for the MKM. We calculated the radiobiological dose for the gross tumor volume (GTVbio) to evaluate the treatment time's effect compared with no treatment time as a reference. The D95 (%) and the Radiation Therapy Oncology Group conformity index (RCI) and Paddick conformity index (PCI) were calculated as dosimetric indices. We used several DNA repair constant rates (a + c) (0.46, 1.0, and 2.0) to assess the radiobiological effect by varying the DNA repair date (a + c) values.

Results: The mean values of D95 (%), RCI, and PCI for GTVbio were 98.8%, 0.90, and 0.80, respectively, and decreased with increasing treatment time. The mean values of D95 (%), RCI, and PCI of GTVbio at 2.0 (a+c) value were 94.9%, 0.71, and 0.49, respectively.

Conclusion: The radiobiological effect of the treatment time on tumors was accurately evaluated with brain SRS using CK.

Advances in knowledge: There has been no published investigation of the radiobiological impact of the longer treatment time with multiple interruptions of SRS using a CK on the target dose distribution in a comparison with the use of a linac. Radiobiological dose assessment that takes into account treatment time in the physical dose in this study may allow more accurate dose assessment in SRS for metastatic brain tumors using CK.

我们使用CyberKnife®(CK)系统对脑转移瘤进行了立体定向放射外科(SRS)中断时间与照射时间的放射生物学效应评估。我们使用了10例接受脑SRS的非小细胞肺癌脑转移患者的DICOM数据和辐射日志文件。我们将治疗时间定义为照射过程中剂量-递送时间和中断时间的总和,并使用微剂量动力学模型(MKM)来评估治疗时间的放射生物学效应。从NCI-H460细胞中获得MKM的生物学参数,即α0、β0和DNA修复恒定速率(a+c)。我们计算了肿瘤总体积的放射生物学剂量(GTVbio),以评估治疗时间与无治疗时间相比的效果,作为参考。D95(%)和放射治疗肿瘤组一致性指数(RCI)和帕迪克一致性指数为剂量测定指数。我们使用了几种DNA修复常数率(a+c)(0.46、1.0和2.0),通过改变DNA修复日期(a+c)值来评估放射生物学效应。GTVbio的D95(%)、RCI和PCI的平均值分别为98.8%、0.90和0.80,并且随着治疗时间的增加而降低。GTVbio在2.0(a+c)值时的D95(%)、RCI和PCI的平均值分别为94.9%、0.71和0.49。使用CK的脑SRS准确评估了治疗时间对肿瘤的放射生物学影响。与使用直线加速器相比,使用CK的SRS多次中断的较长治疗时间对靶剂量分布的放射生物学效应尚未发表研究。在本研究中,考虑物理剂量中的治疗时间的放射生物学剂量评估可能允许使用CK在SRS中对转移性脑肿瘤进行更准确的剂量评估。
{"title":"Radiobiological evaluation considering the treatment time with stereotactic radiosurgery for brain metastases.","authors":"Hisashi Nakano, Takeshi Takizawa, Daisuke Kawahara, Satoshi Tanabe, Satoru Utsunomiya, Motoki Kaidu, Katsuya Maruyama, Shigekazu Takeuchi, Kiyoshi Onda, Masahiko Koizumi, Teiji Nishio, Hiroyuki Ishikawa","doi":"10.1259/bjro.20220013","DOIUrl":"10.1259/bjro.20220013","url":null,"abstract":"<p><strong>Objective: </strong>We evaluated the radiobiological effect of the irradiation time with the interruption time of stereotactic radiosurgery (SRS) using CyberKnife<sup>®</sup> (CK) systemfor brain metastases.</p><p><strong>Methods: </strong>We used the DICOM data and irradiation log file of the 10 patients with brain metastases from non-small-cell lung cancer (NSCLC) who underwent brain SRS. We defined the treatment time as the sum of the dose-delivery time and the interruption time during irradiations, and we used a microdosimetric kinetic model (MKM) to evaluate the radiobiological effects of the treatment time. The biological parameters, <i>i.e.</i> α<sub>0</sub>, β<sub>0</sub>, and the DNA repair constant rate (<i>a</i> + c), were acquired from NCI-H460 cell for the MKM. We calculated the radiobiological dose for the gross tumor volume (GTV<sub>bio</sub>) to evaluate the treatment time's effect compared with no treatment time as a reference. The D95 (%) and the Radiation Therapy Oncology Group conformity index (RCI) and Paddick conformity index (PCI) were calculated as dosimetric indices. We used several DNA repair constant rates (<i>a</i> + c) (0.46, 1.0, and 2.0) to assess the radiobiological effect by varying the DNA repair date (<i>a</i> + c) values.</p><p><strong>Results: </strong>The mean values of D95 (%), RCI, and PCI for GTV<sub>bio</sub> were 98.8%, 0.90, and 0.80, respectively, and decreased with increasing treatment time. The mean values of D95 (%), RCI, and PCI of GTV<sub>bio</sub> at 2.0 (a+c) value were 94.9%, 0.71, and 0.49, respectively.</p><p><strong>Conclusion: </strong>The radiobiological effect of the treatment time on tumors was accurately evaluated with brain SRS using CK.</p><p><strong>Advances in knowledge: </strong>There has been no published investigation of the radiobiological impact of the longer treatment time with multiple interruptions of SRS using a CK on the target dose distribution in a comparison with the use of a linac. Radiobiological dose assessment that takes into account treatment time in the physical dose in this study may allow more accurate dose assessment in SRS for metastatic brain tumors using CK.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":" ","pages":"20220013"},"PeriodicalIF":0.0,"publicationDate":"2022-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10958663/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49185768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"Evolving role of AI in radiation oncology"- special collection - introductory Editorial. “人工智能在放射肿瘤学中的进化作用”——专题集-引言社论
Pub Date : 2022-11-21 eCollection Date: 2022-01-01 DOI: 10.1259/bjro.20229002
Sarah Mattonen, Issam El Naqa, Weigang Hu, Esther Troost
{"title":"\"Evolving role of AI in radiation oncology\"- special collection - introductory Editorial.","authors":"Sarah Mattonen, Issam El Naqa, Weigang Hu, Esther Troost","doi":"10.1259/bjro.20229002","DOIUrl":"10.1259/bjro.20229002","url":null,"abstract":"","PeriodicalId":72419,"journal":{"name":"BJR open","volume":" ","pages":"20229002"},"PeriodicalIF":0.0,"publicationDate":"2022-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10958999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47606590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Whole-body MRI in children: state of the art. 儿童全身核磁共振:最新技术
Pub Date : 2022-10-27 eCollection Date: 2022-01-01 DOI: 10.1259/bjro.20210087
Trevor Gaunt, Paul D Humphries

Whole-body magnetic resonance imaging (WBMRI) is an increasingly popular technique in paediatric imaging. It provides high-resolution anatomical information, with the potential for further exciting developments in acquisition of functional data with advanced MR sequences and hybrid imaging with radionuclide tracers. WBMRI demonstrates the extent of disease in a range of multisystem conditions and, in some cases, disease burden prior to the onset of clinical features. The current applications of WBMRI in children are hereby reviewed, along with suggested anatomical stations and sequence protocols for acquisition.

全身磁共振成像(WBMRI)现在是儿科成像中一种成熟的技术。它提供了高分辨率的解剖信息,有可能在利用先进的MR序列获取功能数据和利用放射性核素示踪剂进行混合成像方面取得进一步令人兴奋的发展。WBMRI显示了一系列多系统条件下的疾病程度,在某些情况下,还显示了临床特征出现前的疾病负担。本文综述了WBMRI在儿童中的当前应用,以及建议的解剖站和采集序列协议。
{"title":"Whole-body MRI in children: state of the art.","authors":"Trevor Gaunt, Paul D Humphries","doi":"10.1259/bjro.20210087","DOIUrl":"10.1259/bjro.20210087","url":null,"abstract":"<p><p>Whole-body magnetic resonance imaging (WBMRI) is an increasingly popular technique in paediatric imaging. It provides high-resolution anatomical information, with the potential for further exciting developments in acquisition of functional data with advanced MR sequences and hybrid imaging with radionuclide tracers. WBMRI demonstrates the extent of disease in a range of multisystem conditions and, in some cases, disease burden prior to the onset of clinical features. The current applications of WBMRI in children are hereby reviewed, along with suggested anatomical stations and sequence protocols for acquisition.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":" ","pages":"20210087"},"PeriodicalIF":0.0,"publicationDate":"2022-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10958622/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44827349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expanding our concept of simulation in radiology: a "Radiology Requesting" session for undergraduate medical students. 扩展放射学模拟的概念:为医科本科生开设的“放射学请求”课程
Pub Date : 2022-10-11 eCollection Date: 2022-01-01 DOI: 10.1259/bjro.20220012
James Hartley, Bobby Agrawal, Karamveer Narang, Edel Kelliher, Elizabeth Lunn, Roshni Bhudia

Objectives: Whilst radiology is central to the modern practice of medicine, graduating doctors often feel unprepared for radiology in practice. Traditional radiological education focuses on image interpretation. Key areas which are undertaught include communication skills relating to the radiology department. We sought to design teaching to fill this important gap.

Methods: We developed a small group session using in situ simulation to enable final and penultimate year medical students to develop radiology-related communication and reasoning skills. Students were given realistic cases, and then challenged to gather further information and decide on appropriate radiology before having the opportunity to call a consultant radiologist on a hospital phone and simulate requesting the appropriate imaging with high fidelity. We evaluated the impact of the teaching through before-and-after Likert scales asking students about their confidence with various aspects of requesting imaging, and qualitatively through open-ended short answer questionnaires.

Results: The session was delivered to 99 students over 24 sessions. Self-reported confidence in discussing imaging increased from an average of 1.7/5 to 3.4/5 as a result of the teaching (p < 0.001) and students perceived that they had developed key skills in identifying and communicating relevant information.

Conclusions: The success of this innovative session suggests that it could form a key part of future undergraduate radiology education, and that the method could be applied in other areas to broaden the application of simulation.

Advances in knowledge: This study highlights a gap in undergraduate medical education. It describes and demonstrates the effectiveness of an intervention to fill this gap.

虽然放射学是现代医学实践的核心,但毕业的医生往往对放射学的实践感到措手不及。传统的放射学教育侧重于图像解读。教授的主要领域包括与放射科有关的沟通技巧。我们试图通过设计教学来填补这一重要空白。我们开发了一个使用现场模拟的小组会议,使最后一年和第二年的医学生能够发展与放射学相关的沟通和推理技能。学生们得到了真实的病例,然后在有机会打电话给医院的放射科顾问并模拟要求高保真的适当成像之前,挑战收集进一步的信息并决定适当的放射学。我们通过前后李克特量表评估教学的影响,询问学生对要求成像的各个方面的信心,并通过开放式简短回答问卷进行定性评估。该课程分24节向99名学生讲授。自我报告的讨论成像的信心从平均1.7/5增加到3.4/5,作为教学的结果(p < 0.001),学生们认为他们已经发展了识别和交流相关信息的关键技能。这一创新课程的成功表明,它可以成为未来本科放射学教育的重要组成部分,并且该方法可以应用于其他领域,以扩大模拟的应用范围。本研究突出了本科医学教育的差距。它描述并展示了填补这一空白的干预措施的有效性。
{"title":"Expanding our concept of simulation in radiology: a \"Radiology Requesting\" session for undergraduate medical students.","authors":"James Hartley, Bobby Agrawal, Karamveer Narang, Edel Kelliher, Elizabeth Lunn, Roshni Bhudia","doi":"10.1259/bjro.20220012","DOIUrl":"10.1259/bjro.20220012","url":null,"abstract":"<p><strong>Objectives: </strong>Whilst radiology is central to the modern practice of medicine, graduating doctors often feel unprepared for radiology in practice. Traditional radiological education focuses on image interpretation. Key areas which are undertaught include communication skills relating to the radiology department. We sought to design teaching to fill this important gap.</p><p><strong>Methods: </strong>We developed a small group session using <i>in situ</i> simulation to enable final and penultimate year medical students to develop radiology-related communication and reasoning skills. Students were given realistic cases, and then challenged to gather further information and decide on appropriate radiology before having the opportunity to call a consultant radiologist on a hospital phone and simulate requesting the appropriate imaging with high fidelity. We evaluated the impact of the teaching through before-and-after Likert scales asking students about their confidence with various aspects of requesting imaging, and qualitatively through open-ended short answer questionnaires.</p><p><strong>Results: </strong>The session was delivered to 99 students over 24 sessions. Self-reported confidence in discussing imaging increased from an average of 1.7/5 to 3.4/5 as a result of the teaching (<i>p</i> < 0.001) and students perceived that they had developed key skills in identifying and communicating relevant information.</p><p><strong>Conclusions: </strong>The success of this innovative session suggests that it could form a key part of future undergraduate radiology education, and that the method could be applied in other areas to broaden the application of simulation.</p><p><strong>Advances in knowledge: </strong>This study highlights a gap in undergraduate medical education. It describes and demonstrates the effectiveness of an intervention to fill this gap.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":" ","pages":"20220012"},"PeriodicalIF":0.0,"publicationDate":"2022-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10958647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48493377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RRIMS: Radiation Risk In Mammography Screening - a novel model for predicting the lifetime dose and risk of radiation-induced breast cancer from the first screening visit. RRIMS:乳腺摄影筛查中的辐射风险——一种新的模型,用于预测首次筛查时放射性乳腺癌症的终生剂量和风险
Pub Date : 2022-09-29 eCollection Date: 2022-01-01 DOI: 10.1259/bjro.20220028
Sahand Hooshmand, Warren M Reed, Mo'ayyad E Suleiman, Patrick C Brennan

Objectives: Radiation Risk In Mammography Screening (RRIMS) builds on the prototype, formerly known as Breast-iRRISC, to develop a model that aims to establish a dose and risk profile for females by calculating their lifetime mean glandular dose (MGD) for each age of screening between 40 and 75 years, using only the information from her first screening visit. This is then used to allocate her to a dose category and estimate the lifetime risk of radiation-induced breast cancer incidence and mortality for a population of females in that category.

Methods: This model training was developed using a large dataset of Hologic images containing a total of 20,232 images from 5,076 visits from 4,154 females. The female's breast characteristics and exposure parameters were extracted from the images to calculate the female's MGD throughout a lifetime of screening from just her first screening visit, using modelling of various parameters and their change through time.

Results: This development has ultimately provided a model that uses the female's first screening visit to calculate the received MGD for all ages of potential screening. This has enabled the allocation of females to either a low-, medium-, or high-dose category, ultimately followed by the lifetime effective risk (LER) estimation for any screening attendance pattern. A female in the low-dose category undergoing biennial screening from 50 to 74 years would expect a risk of radiation-induced breast cancer incidence and mortality of 8.64 and 2.61 cases per 100,000 females, respectively. Similarly, a female in the medium- or high-dose category undergoing the same regimen would expect an incidence and mortality risk of 11.76 and 3.55, and 15.08 and 4.55 cases per 100,000 females, respectively.

Conclusions: This novel approach of establishing a female's dose profile and lifetime risk from a single visit will further assist females in their informed consent on breast screening attendance and help inform policy-makers when exploring the benefits and drawbacks of various screening patterns and frequencies.

Advances in knowledge: RRIMS is a novel tool that enables the assessment of a female's lifetime dose and risk profile using only the information from her first screening visit.

乳腺造影筛查风险(RRIMS)建立在前身为乳腺iRRISC的原型基础上,旨在开发一个模型,通过仅使用女性首次筛查访问的信息,计算40至75岁之间每个筛查年龄的终生平均腺剂量(MGD),来建立女性的剂量和风险状况。然后将其分配到一个剂量类别,并估计该类别女性的放射性乳腺癌癌症发病率和死亡率的终身风险。该模型训练是使用Hologic图像的大型数据集开发的,该数据集包含4154名女性5076次就诊的20232张图像。从图像中提取女性的乳房特征和暴露参数,通过对各种参数及其随时间变化的建模,计算女性在第一次筛查访视后的整个筛查过程中的MGD。这一发展最终提供了一个模型,该模型使用女性的首次筛查访视来计算所有年龄段潜在筛查的MGD。这使得女性能够被分配到低、中或高剂量类别,最终对任何筛查参与模式进行终身有效风险(LER)估计。低剂量类别的女性在50至74岁之间接受两年一次的筛查,预计辐射诱发的癌症发病率和死亡率分别为8.64和2.61例/10万。同样,接受相同方案的中剂量或高剂量组女性的发病率和死亡率风险分别为每100000名女性11.76例和3.55例,15.08例和4.55例。这种从一次就诊中确定女性剂量谱和终身风险的新方法将进一步帮助女性在知情同意的情况下参加乳腺筛查,并有助于决策者在探索各种筛查模式和频率的利弊时了解情况。RRIMS是一种新的工具,可以仅使用女性第一次筛查访问的信息来评估女性的终身剂量和风险状况。
{"title":"RRIMS: Radiation Risk In Mammography Screening - a novel model for predicting the lifetime dose and risk of radiation-induced breast cancer from the first screening visit.","authors":"Sahand Hooshmand, Warren M Reed, Mo'ayyad E Suleiman, Patrick C Brennan","doi":"10.1259/bjro.20220028","DOIUrl":"10.1259/bjro.20220028","url":null,"abstract":"<p><strong>Objectives: </strong><b>R</b>adiation <b>R</b>isk <b>I</b>n <b>M</b>ammography <b>S</b>creening (<b>RRIMS</b>) builds on the prototype, formerly known as Breast-iRRISC, to develop a model that aims to establish a dose and risk profile for females by calculating their lifetime mean glandular dose (MGD) for each age of screening between 40 and 75 years, using only the information from her first screening visit. This is then used to allocate her to a dose category and estimate the lifetime risk of radiation-induced breast cancer incidence and mortality for a population of females in that category.</p><p><strong>Methods: </strong>This model training was developed using a large dataset of Hologic images containing a total of 20,232 images from 5,076 visits from 4,154 females. The female's breast characteristics and exposure parameters were extracted from the images to calculate the female's MGD throughout a lifetime of screening from just her first screening visit, using modelling of various parameters and their change through time.</p><p><strong>Results: </strong>This development has ultimately provided a model that uses the female's first screening visit to calculate the received MGD for all ages of potential screening. This has enabled the allocation of females to either a low-, medium-, or high-dose category, ultimately followed by the lifetime effective risk (LER) estimation for any screening attendance pattern. A female in the low-dose category undergoing biennial screening from 50 to 74 years would expect a risk of radiation-induced breast cancer incidence and mortality of 8.64 and 2.61 cases per 100,000 females, respectively. Similarly, a female in the medium- or high-dose category undergoing the same regimen would expect an incidence and mortality risk of 11.76 and 3.55, and 15.08 and 4.55 cases per 100,000 females, respectively.</p><p><strong>Conclusions: </strong>This novel approach of establishing a female's dose profile and lifetime risk from a single visit will further assist females in their informed consent on breast screening attendance and help inform policy-makers when exploring the benefits and drawbacks of various screening patterns and frequencies.</p><p><strong>Advances in knowledge: </strong>RRIMS is a novel tool that enables the assessment of a female's lifetime dose and risk profile using only the information from her first screening visit.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":" ","pages":"20220028"},"PeriodicalIF":0.0,"publicationDate":"2022-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10958679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49268188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Statistical considerations for repeatability and reproducibility of quantitative imaging biomarkers. 定量成像生物标志物的重复性和再现性的统计考虑。
Pub Date : 2022-08-22 eCollection Date: 2022-01-01 DOI: 10.1259/bjro.20210083
Shangyuan Ye, Jeong Youn Lim, Wei Huang

Quantitative imaging biomarkers (QIBs) are increasingly used in clinical studies. Because many QIBs are derived through multiple steps in image data acquisition and data analysis, QIB measurements can produce large variabilities, posing a significant challenge in translating QIBs into clinical trials, and ultimately, clinical practice. Both repeatability and reproducibility constitute the reliability of a QIB measurement. In this article, we review the statistical aspects of repeatability and reproducibility of QIB measurements by introducing methods and metrics for assessments of QIB repeatability and reproducibility and illustrating the impact of QIB measurement error on sample size and statistical power calculations, as well as predictive performance with a QIB as a predictive biomarker.

定量成像生物标志物(QIB)越来越多地用于临床研究。由于许多QIB是通过图像数据采集和数据分析的多个步骤得出的,因此QIB测量可能会产生很大的可变性,这对将QIB转化为临床试验以及最终的临床实践构成了重大挑战。可重复性和再现性都构成了QIB测量的可靠性。在这篇文章中,我们回顾了QIB测量的重复性和再现性的统计方面,介绍了评估QIB重复性和重现性的方法和指标,并说明了QIB的测量误差对样本量和统计功率计算的影响,以及将QIB作为预测性生物标志物的预测性能。
{"title":"Statistical considerations for repeatability and reproducibility of quantitative imaging biomarkers.","authors":"Shangyuan Ye,&nbsp;Jeong Youn Lim,&nbsp;Wei Huang","doi":"10.1259/bjro.20210083","DOIUrl":"10.1259/bjro.20210083","url":null,"abstract":"<p><p>Quantitative imaging biomarkers (QIBs) are increasingly used in clinical studies. Because many QIBs are derived through multiple steps in image data acquisition and data analysis, QIB measurements can produce large variabilities, posing a significant challenge in translating QIBs into clinical trials, and ultimately, clinical practice. Both repeatability and reproducibility constitute the reliability of a QIB measurement. In this article, we review the statistical aspects of repeatability and reproducibility of QIB measurements by introducing methods and metrics for assessments of QIB repeatability and reproducibility and illustrating the impact of QIB measurement error on sample size and statistical power calculations, as well as predictive performance with a QIB as a predictive biomarker.</p>","PeriodicalId":72419,"journal":{"name":"BJR open","volume":" ","pages":"20210083"},"PeriodicalIF":0.0,"publicationDate":"2022-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40712920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
BJR open
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1